I think the Gilead ship has sailed...Gilead have moved on from BIT imo
J&J is a pretty impressive outfit in terms of revenue and seems like quite the possibility with both MM and SP having previous connections
Dr Susan M Pond AM, MD DSc, FTSE FAHMS Independent and Non-Executive Director Dr Pond has a strong scientific and commercial background having held executive positions in the biotechnology and pharmaceutical industry for 12 years, most recently as Chairman and Managing Director of Johnson & Johnson Research Pty Limited (2003-2009). Previous non-executive positions include chair of AusBiotech Limited and director of Australian Nuclear Science and Technology Organisation, Wound Management Innovation CRC and Australian Academy of Technological Sciences and Engineering (ATSE). Dr Pond also served as a board member of Commercialisation Australia and Innovation Australia.
Dr Michelle Miller, BSc, MSc, PhD GCertAppFin (Finsia) Chief Executive Officer and Managing Director Dr Miller has worked for over 25 years in the bioscience industry, with extensive experience in commercial drug development. She completed her PhD in the Faculty of Medicine at Sydney University investigating molecular models of cancer development. Her experience includes several years at Johnson and Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a specialist bioscience venture capital fund.
Below a list of top Pharma by revenue ($bn)
BIT Price at posting:
8.5¢ Sentiment: None Disclosure: Held
